Global Tuberculosis Drug Market 2017-2021

結核治療薬の世界市場2017-2021

◆タイトル:Global Tuberculosis Drug Market 2017-2021
◆商品コード:IRTNTR11381
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年2月10日
◆ページ数:76
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:世界
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,500 ⇒換算¥508,500見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、結核治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、結核治療薬の世界市場規模及び予測、薬剤種類別分析、地域別分析/市場規模、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Tuberculosis DrugTuberculosis (TB) is caused by Mycobacterium tuberculosis and often affects the lungs. It spreads from person to person through the air in the form of a cough, sneeze or spit. TB affects adults more when compared with children.

Technavio’s analysts forecast the global tuberculosis drug market to grow at a CAGR of 3.17% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global tuberculosis drug market for 2017-2021. To calculate the market size, the report considers the volume and services.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Tuberculosis Drug Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Lupin
• Otsuka Novel Products
• Pfizer
• Sandoz
• Sanofi

[Other prominent vendors]
• AstraZeneca
• Archivel Farma
• bioMérieux
• Cepheid
• EIKEN CHEMICAL
• Epistem

[Market driver]
• Increase in outbreak of TB-HIV co-infections
• For a full, detailed list, view our report

[Market challenge]
• Insufficient demand and high drug cost in developed countries
• For a full, detailed list, view our report

[Market trend]
• Focus on development of shorter TB drug regimens
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents

PART 01: Executive summary

PART 02: Scope of  the report

PART 03: Research Methodology

PART 04: Introduction

Key market highlights

PART 05: Key pipeline

PART 06: Market landscape

Market overview
Market size and forecast
Five forces analysis

PART 07: High burden countries (HBCs)

Categorization of HBCs

PART 08: TB diagnostics

Overview

PART 09: Market segmentation by disease type

Global latent TB market
Global active TB market

PART 10: Market segmentation by drug class

Global first-line anti-TB drugs market
Global second-line anti-TB drugs market

PART 11: Geographical segmentation

TB drugs market in Americas
TB drugs market in EMEA
TB drug market in APAC

PART 12: Market drivers

Increase in outbreak of TB-HIV co-infections
Emergence of MDR-TB and XDR-TB strains
Increasing incidence of TB in Africa and Asia

PART 13: Impact of drivers

PART 14: Market challenges

Insufficient demand and high drug cost in developed countries
Liberal regulations and lack of awareness in developing countries
Limited diagnostic procedures

PART 15: Impact of drivers and challenges

PART 16: Market trends

Increased spending on TB diagnostic kits
Focus on development of shorter TB drug regimens
Increased focus on TB vaccine development

PART 17: Vendor landscape

Competitive scenario
Key news

PART 18: Key vendor analysis

Lupin
Otsuka Novel Products
Pfizer
Sandoz
Sanofi
Other prominent vendors

PART 19: Appendix

List of abbreviations

PART 20: Explore Technavio

[List of Exhibits]

Exhibit 01: Pipeline analysis

Exhibit 02: Key clinical trials

Exhibit 03: Global TB drugs market snapshot

Exhibit 04: Global TB drugs market 2016-2021 ($ millions)

Exhibit 05: Opportunity analysis in global TB drugs market

Exhibit 06: Five forces analysis

Exhibit 07: List of major HBCs

Exhibit 08: Advanced technologies used for TB diagnostics

Exhibit 09: Tests recommended for diagnosis of active TB

Exhibit 10: Drugs used as first-line anti-TB agents

Exhibit 11: Global first-line anti-TB drugs market 2016-2021 ($ millions)

Exhibit 12: Drugs used as second-line anti-TB agents

Exhibit 13: Global second-line anti-TB drugs market 2016-2021 ($ millions)

Exhibit 14: TB drugs market scenario in Americas

Exhibit 15: TB drugs market in Americas 2016-2021 ($ millions)

Exhibit 16: Number of TB cases reported in US 2010-2015

Exhibit 17: TB drugs market scenario in EMEA

Exhibit 18: TB drugs market in EMEA 2016-2021 ($ millions)

Exhibit 19: TB drugs market scenario in APAC

Exhibit 20: TB drugs market in APAC 2016-2021 ($ millions)

Exhibit 21: Impact of drivers

Exhibit 22: Impact of drivers and challenges

Exhibit 23: Testing process in BCG vaccines

Exhibit 24: Competitive structure analysis of global TB drug market 2016

Exhibit 25: Lupin: Key highlights

Exhibit 26: Lupin: Strength assessment

Exhibit 27: Lupin: Strategy assessment

Exhibit 28: Lupin: Opportunity assessment

Exhibit 29: Otsuka Novel Products: Key highlights

Exhibit 30: Otsuka Novel Products: Strength assessment

Exhibit 31: Otsuka Novel Products: Strategy assessment

Exhibit 32: Pfizer: Key highlights

Exhibit 33: Pfizer: Strength assessment

Exhibit 34: Pfizer: Strategy assessment

Exhibit 35: Pfizer: Opportunity assessment

Exhibit 36: Sandoz: Key highlights

Exhibit 37: Sandoz: Strength assessment

Exhibit 38: Sandoz: Strategy assessment

Exhibit 39: Sandoz: Opportunity assessment

Exhibit 40: Sanofi: Key highlights

Exhibit 41: Sanofi: Strength assessment

Exhibit 42: Sanofi: Strategy assessment

Exhibit 43: Sanofi: Opportunity assessment



【資料のキーワード】

結核、結核治療薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[結核治療薬の世界市場2017-2021] (Global Tuberculosis Drug Market 2017-2021 / IRTNTR11381)販売に関する免責事項
[結核治療薬の世界市場2017-2021] (Global Tuberculosis Drug Market 2017-2021 / IRTNTR11381)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆